Phase 2
N=58
Cefixime for Alternative Syphilis Treatment
Syphilis · Early Syphilis
Bottom Line
View on ClinicalTrials.gov: NCT03660488 ↗Enrolled (actual)
58
Serious AEs
1.7%
Results posted
Jul 2022
Primary outcome: Primary: Treatment Response — 14; 13 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cefixime 400 milligram Oral Capsule [Suprax] (Drug); Benzathine Penicillin G (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jan 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Response |
14; 13 | — |
Summary
The goal of the study is to evaluate the efficacy of oral cefixime as an alternative treatment for syphilis infection.
One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema Pallidum Particle Agglutination assay and RPR titer ≥ 1/8) will be recruited. Participants will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime.
During the study, participants will visit the clinic up to 5 times; at baseline visit, at 3, 6, 12 months after treatment initiation. Participants of the cefixime group will be required to visit the clinic 14 days after treatment initiation. In each visit, participants will be asked about current symptoms and do laboratory tests for syphilis (RPR). Subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a positive treatment response.
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older and able to provide informed consent
- Cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment.
- HIV infected individuals willing to participate in the study must have CD4 count ≥350 cells/μl within the last 4 weeks and be virally suppressed (i.e., viral load ≤ 200 copies/mL) for HIV for the 6 months prior to enrolment with the most recent results within the last 4 weeks. inclusion
- Non-cephalosporin allergic
- Able to travel to the clinic once a day or be available for phone calls or receive text messages for at least 7-10 days and willing to attend follow-up visits
- Able to swallow pills
Exclusion Criteria
- Pregnancy or positive pregnancy test
- Serofast RPR titer (prior titer 1: 8 or greater)
- Recent (less than 7 days) or concomitant antimicrobial therapy with activity against syphilis.
- Cephalosporin allergy: previous episode of flushing, urticaria, angioedema, rhinitis, bronchospasm, and anaphylactic shock, rash after taking cephalosporin.
- Penicillin allergy: previous episode of flushing, urticaria, angioedema, rhinitis, bronchospasm, and anaphylactic shock, rash after receiving Penicillin.
- Has a medical condition or other factor that might affect their ability to follow the protocol
Data sourced from ClinicalTrials.gov (NCT03660488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.